Optimizing Entyvio Prior Authorization for Orthopedics

The Intersection of Entyvio and Orthopedic Care

Entyvio (vedolizumab) is an anti-integrin biologic primarily indicated for moderate to severe ulcerative colitis and Crohn's disease. While not a direct orthopedic treatment, orthopedic practices often manage patients with co-morbid IBD who may be on Entyvio, particularly when addressing extra-intestinal manifestations affecting joints or the spine, or when planning orthopedic procedures for these complex patients. Effective prior authorization for such biologics is critical for comprehensive patient management.

Typical Entyvio Prior Authorization Documentation

• Confirmation of IBD diagnosis (Crohn's disease or ulcerative colitis) by a gastroenterologist.
• Documentation of failed conventional therapies (e.g., corticosteroids, immunomodulators) or contraindications to their use.
• Evidence of moderate to severe disease activity, often supported by endoscopy reports, imaging, and disease activity scores.
• Consultation notes from the prescribing gastroenterologist detailing treatment plan and medical necessity.
• Absence of contraindications for Entyvio, such as active infections or hypersensitivity.

Challenges for Orthopedic Practices Managing Biologic PAs

For orthopedic practices, managing prior authorizations for biologics like Entyvio can present unique challenges. These may include a lack of familiarity with gastrointestinal-specific clinical criteria, the need to coordinate extensive documentation from multiple specialties, and integrating these complex PA workflows with existing high-volume orthopedic PA processes for imaging, surgery, and DME. This can strain PA coordinator staffing and impact pre-operative scheduling pressure, as highlighted in general orthopedic PA challenges.

Mitigating Entyvio PA Denials in a Multidisciplinary Context

• Insufficient documentation of failed conventional therapy trials.
• Lack of objective disease activity scores or endoscopic evidence.
• Missing or incomplete consultation notes from the prescribing specialist.
• Failure to address payer-specific step therapy protocols.
• Documentation gaps regarding patient's response to prior biologic agents, if applicable.

Klivira's Role in Streamlining Biologic and Orthopedic PAs

Klivira's platform is engineered to automate the data extraction and submission processes for complex prior authorizations, including those for biologics like Entyvio. By integrating with leading EMRs via SMART on FHIR, Klivira can efficiently gather critical patient data—such as diagnosis codes, medication history, and specialist notes—necessary for biologic PA approval. This capability extends to orchestrating multi-step PA cascades, common in orthopedics (e.g., imaging then surgery), and adapting to diverse payer policy libraries, enhancing efficiency across all PA types.

Integrating Entyvio PA into Orthopedic Workflows

Klivira helps orthopedic practices manage the entire PA lifecycle, from initial submission to facilitating peer-to-peer review scheduling for clinical-necessity denials. For biologics, this includes ensuring all required clinical documentation, such as evidence of conservative-care trial failures (for IBD, this refers to conventional therapies), is systematically gathered and presented. By reducing the administrative burden associated with complex PAs, Klivira enables orthopedic teams to focus on patient care, whether for a joint replacement or coordinating care for a patient on Entyvio.